Aurora Cannabis (ACB) Total Non-Current Liabilities (2018 - 2025)
Aurora Cannabis (ACB) posted quarterly Total Non-Current Liabilities of $44.1 million for Q4 2025, down 57.7% year-on-year from $104.3 million in Q4 2024, and down 7.5% on a QoQ basis from $47.7 million in Q3 2025.
Aurora Cannabis (ACB) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends
Aurora Cannabis (ACB) has reported Total Non-Current Liabilities for 8 consecutive years, with $44.1 million the latest figure, recorded in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 57.7% year-over-year to $44.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $44.1 million (down 57.7% YoY) and the FY2025 annual result came in at $95.8 million, down 14.58% from the prior year.
- Total Non-Current Liabilities fell to $44.1 million in Q4 2025 per ACB's latest filing, from $47.7 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for ACB reached as high as $438.0 million in Q3 2022 and fell as low as -$4.2 million in Q2 2022.
- A 5-year average of $194.8 million and a median of $151.5 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities slumped 185.49% — and 2023, when it jumped 3688.19%.
- Year by year, Total Non-Current Liabilities stood at $419.1 million in 2021, then retreated by 25.22% to $313.4 million in 2022, then slumped by 51.62% to $151.6 million in 2023, then tumbled by 31.19% to $104.3 million in 2024, then plunged by 57.7% to $44.1 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $44.1 million, $47.7 million, and $66.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Aurora Cannabis | 1.11 Bn | 1.03 Bn | 21.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 44.12 Mn |
| Sep 30, 2025 | 47.70 Mn |
| Jun 30, 2025 | 66.59 Mn |
| Mar 31, 2025 | 92.84 Mn |
| Dec 31, 2024 | 104.32 Mn |
| Sep 30, 2024 | 116.71 Mn |
| Jun 30, 2024 | 119.54 Mn |
| Mar 31, 2024 | 171.57 Mn |
| Dec 31, 2023 | 151.60 Mn |
| Sep 30, 2023 | 151.35 Mn |
| Jun 30, 2023 | 152.26 Mn |
| Mar 31, 2023 | 296.00 Mn |
| Dec 31, 2022 | 313.37 Mn |
| Sep 30, 2022 | 438.02 Mn |
| Jun 30, 2022 | -4.24 Mn |
| Mar 31, 2022 | 378.58 Mn |
| Dec 31, 2021 | 419.08 Mn |
| Sep 30, 2021 | 422.99 Mn |
| Jun 30, 2021 | -1.49 Mn |
| Mar 31, 2021 | 415.25 Mn |